share_log

Novo Integrated Sciences | 10-Q: Q3 2024 Earnings Report

Novo Integrated Sciences | 10-Q: Q3 2024 Earnings Report

Novo Integrated Sciences | 10-Q：2024財年三季報
美股SEC公告 ·  2024/07/20 05:11

Moomoo AI 已提取核心訊息

Novo Integrated Sciences reported Q3 FY2024 revenues of $3.15 million, down 4% from $3.29 million in Q3 FY2023. Healthcare services revenue increased 8.1% while product sales declined. Gross profit decreased to $896,893 from $1.31 million year-over-year, with cost of revenues rising 14% to $2.25 million.Operating expenses increased 25% to $3.42 million due to inflationary impacts. The company recorded a significant net loss of $13.74 million compared to $1.49 million loss in Q3 FY2023, primarily due to a $6.72 million loss from derivative liability fair value changes, $2.90 million debt discount amortization, and $1.41 million foreign exchange losses.The company secured new financing through convertible notes, including a $6.21 million note from Streeterville Capital in April 2024. Management noted concerns about going concern due to recurring losses and negative cash flows, though they are pursuing equity/debt financing options. The company must also address Nasdaq's minimum bid price compliance requirement by August 2024.
Novo Integrated Sciences reported Q3 FY2024 revenues of $3.15 million, down 4% from $3.29 million in Q3 FY2023. Healthcare services revenue increased 8.1% while product sales declined. Gross profit decreased to $896,893 from $1.31 million year-over-year, with cost of revenues rising 14% to $2.25 million.Operating expenses increased 25% to $3.42 million due to inflationary impacts. The company recorded a significant net loss of $13.74 million compared to $1.49 million loss in Q3 FY2023, primarily due to a $6.72 million loss from derivative liability fair value changes, $2.90 million debt discount amortization, and $1.41 million foreign exchange losses.The company secured new financing through convertible notes, including a $6.21 million note from Streeterville Capital in April 2024. Management noted concerns about going concern due to recurring losses and negative cash flows, though they are pursuing equity/debt financing options. The company must also address Nasdaq's minimum bid price compliance requirement by August 2024.
Novo Integrated Sciences報告了2024財年第三季度的營業收入爲315萬，較2023財年第三季度的329萬下降了4%。醫療服務的營業收入增長了8.1%，而產品銷售則出現下滑。毛利潤從去年同期的131萬下降至896,893，營業收入成本上升了14%，達到225萬。由於通貨膨脹的影響，營業費用增加了25%，達到342萬。公司報告了1374萬的重大淨虧損，而2023財年第三季度的虧損爲149萬，主要是由於衍生負債公允價值變動造成的672萬虧損、290萬的債務折扣攤銷，以及141萬的匯率期貨損失。公司通過可轉換票據獲得了新的融資，包括2024年4月來自Streeterville Capital的621萬票據。管理層表示，由於持續虧損和負現金流的風險，存在持續經營的擔憂，儘管他們正在追求股權/債務融資的期權。公司還必須在2024年8月之前解決納斯達克的最低買盤價格合規要求。
Novo Integrated Sciences報告了2024財年第三季度的營業收入爲315萬，較2023財年第三季度的329萬下降了4%。醫療服務的營業收入增長了8.1%，而產品銷售則出現下滑。毛利潤從去年同期的131萬下降至896,893，營業收入成本上升了14%，達到225萬。由於通貨膨脹的影響，營業費用增加了25%，達到342萬。公司報告了1374萬的重大淨虧損，而2023財年第三季度的虧損爲149萬，主要是由於衍生負債公允價值變動造成的672萬虧損、290萬的債務折扣攤銷，以及141萬的匯率期貨損失。公司通過可轉換票據獲得了新的融資，包括2024年4月來自Streeterville Capital的621萬票據。管理層表示，由於持續虧損和負現金流的風險，存在持續經營的擔憂，儘管他們正在追求股權/債務融資的期權。公司還必須在2024年8月之前解決納斯達克的最低買盤價格合規要求。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    英偉達
    NVDA
    -- 109.670
    特斯拉
    TSLA
    -- 263.550
    Palantir
    PLTR
    -- 85.850
    亞馬遜
    AMZN
    -- 192.720
    CoreWeave
    CRWV
    -- 40.000
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    FOMC維持利率但不確定性高企：美股後市走向如何？
    🎙️討論 1. 美聯儲強調政策路徑存在「高度不確定性」，你更關注利率預期變化還是經濟數據對市場的短期影響？ 2. 若核心通脹維持高位，哪類板塊更具交易機會——防禦型股票還是科技成長股？ 展开
    聯邦公開市場委員會新聞發佈會，2025年3月19日